BACKGROUND: Aberrant signaling mediated by the mammalian target of rapamycin (mTOR) occurs at high frequency in hepatocellular carcinoma (HCC), indicating that mTOR is a candidate for targeted therapy. mTOR forms two complexes called mTORC1 (mTOR complexed with raptor) and mTORC2 (mTOR complexed with rictor). There are minor studies of the expression kinetics of mTORC1 and mTORC2 in HCC. METHODS: We studied 62 patients with HCC who underwent curative resection. We used univariate and multivariate analyses to identify factors that potentially influence disease and overall survival after hepatectomy. The mRNA and protein levels of mTOR, rictor and raptor in cancer and non-cancer tissues were analyzed using quantitative RT-PCR, immunohistochemistry and Western blotting. RESULTS/ CONCLUSION: High ratio of the levels of rictor and raptor mRNAs in tumors was identified as independent prognostic indicators for disease-free survival. Low and high levels of preoperative serum albumin and mTOR mRNA in the tumor, respectively, were identified as independent indicators of overall survival. HCC is likely to recur early after hepatic resection in patients with high levels of mTOR and rictor mRNAs and high rictor/raptor ratios in cancer tissues. We conclude that analysis of mTOR expression in cancer tissues represents an essential strategy to predict HCC recurrence after curative treatment.
BACKGROUND: Aberrant signaling mediated by the mammalian target of rapamycin (mTOR) occurs at high frequency in hepatocellular carcinoma (HCC), indicating that mTOR is a candidate for targeted therapy. mTOR forms two complexes called mTORC1 (mTOR complexed with raptor) and mTORC2 (mTOR complexed with rictor). There are minor studies of the expression kinetics of mTORC1 and mTORC2 in HCC. METHODS: We studied 62 patients with HCC who underwent curative resection. We used univariate and multivariate analyses to identify factors that potentially influence disease and overall survival after hepatectomy. The mRNA and protein levels of mTOR, rictor and raptor in cancer and non-cancer tissues were analyzed using quantitative RT-PCR, immunohistochemistry and Western blotting. RESULTS/ CONCLUSION: High ratio of the levels of rictor and raptor mRNAs in tumors was identified as independent prognostic indicators for disease-free survival. Low and high levels of preoperative serum albumin and mTOR mRNA in the tumor, respectively, were identified as independent indicators of overall survival. HCC is likely to recur early after hepatic resection in patients with high levels of mTOR and rictor mRNAs and high rictor/raptor ratios in cancer tissues. We conclude that analysis of mTOR expression in cancer tissues represents an essential strategy to predict HCC recurrence after curative treatment.
Authors: Yonghao Yu; Sang-Oh Yoon; George Poulogiannis; Qian Yang; Xiaoju Max Ma; Judit Villén; Neil Kubica; Gregory R Hoffman; Lewis C Cantley; Steven P Gygi; John Blenis Journal: Science Date: 2011-06-10 Impact factor: 47.728
Authors: Zhi Hong Lu; Mark B Shvartsman; Andrew Y Lee; Jenny M Shao; Mollianne M Murray; Raleigh D Kladney; Dong Fan; Stan Krajewski; Gary G Chiang; Gordon B Mills; Jeffrey M Arbeit Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: Wolfgang Sieghart; Thorsten Fuereder; Katharina Schmid; Daniel Cejka; Johannes Werzowa; Fritz Wrba; Xiaowei Wang; Diego Gruber; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Volker Wacheck Journal: Transplantation Date: 2007-02-27 Impact factor: 4.939
Authors: Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet Journal: Gastroenterology Date: 2008-08-20 Impact factor: 22.682
Authors: Pengda Liu; Wenjian Gan; Hiroyuki Inuzuka; Adam S Lazorchak; Daming Gao; Omotooke Arojo; Dou Liu; Lixin Wan; Bo Zhai; Yonghao Yu; Min Yuan; Byeong Mo Kim; Shavali Shaik; Suchithra Menon; Steven P Gygi; Tae Ho Lee; John M Asara; Brendan D Manning; John Blenis; Bing Su; Wenyi Wei Journal: Nat Cell Biol Date: 2013-10-27 Impact factor: 28.824
Authors: Meghan Morrison Joly; Donna J Hicks; Bayley Jones; Violeta Sanchez; Monica Valeria Estrada; Christian Young; Michelle Williams; Brent N Rexer; Dos D Sarbassov; William J Muller; Dana Brantley-Sieders; Rebecca S Cook Journal: Cancer Res Date: 2016-04-25 Impact factor: 12.701
Authors: Katharina M Schmidt; Claus Hellerbrand; Petra Ruemmele; Christoph W Michalski; Bo Kong; Alexander Kroemer; Christina Hackl; Hans J Schlitt; Edward K Geissler; Sven A Lang Journal: Oncotarget Date: 2017-04-11
Authors: Katharina M Schmidt; Peter Dietrich; Christina Hackl; Jessica Guenzle; Peter Bronsert; Christine Wagner; Stefan Fichtner-Feigl; Hans J Schlitt; Edward K Geissler; Claus Hellerbrand; Sven A Lang Journal: Neoplasia Date: 2018-11-04 Impact factor: 5.715